Congenital generalized lipodystrophy is considered to be a diencephalic syndrome with disturbance of hypothalamic transmitters. After puberty and arrest of growth the patients develop a serious untreatable diabetes mellitus. One of our patients, a girl 15 years of age, developed a lipodystrophic diabetes with fasting blood glucose levels above 300 mg/100 ml, increased serum insulin with insulin resistance, and hyperlipidaemia. Daily administration of fenfluramine gave a dramatic improvement. The voracious hunger and profuse perspiration were reduced, the patient's serum lipids became normal, her blood glucose fell, and her sensitivity to exogenous insulin increased. A normalization of the urinary excretion of the serotonin metabolite, 5-OH-indole acetic acid, was observed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A very low carbohydrate diet improved metabolic profile in congenital generalized lipodystrophy type 4.
Endocrinol Diabetes Metab Case Rep
January 2025
Summary: A 17-year-old girl presented with recurrent attacks of acute pancreatitis, associated with severe hyperglycemia and hypertriglyceridemia, despite being on intensive insulin therapy for the last 10 years. She had severe acanthosis nigricans, generalized loss of subcutaneous fat and prominent veins over extremities. The serum levels of glucose and triglyceride did not reduce significantly, even with maximally tolerated doses of metformin (2 g), pioglitazone (45 mg) and fenofibrate (160 mg), not uncommonly seen in poor rural families in West Bengal, India.
View Article and Find Full Text PDFAnxiety and Body Image Distress in a Type 1 Diabetes Patient With Insulin-Induced Lipodystrophy.
Cureus
December 2024
Emergency Department, Bahria International Hospital, Rawalpindi, PAK.
This case report presents a rare instance of a 28-year-old female patient with insulin-induced abdominal lipodystrophy, who presented to the emergency department with symptoms of an anxiety attack triggered by body image distress. She was diagnosed with type 1 diabetes at the age of eight years. For the past 10 years, she has been using insulin glargine and insulin lispro, injecting roughly five times per day.
View Article and Find Full Text PDFPreclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy.
Gene Ther
September 2024
The Rowett Institute, University of Aberdeen, Aberdeen, AB25 2ZD, UK.
Article Synopsis
- Lipodystrophy is a serious condition where individuals cannot maintain fat tissue, leading to severe metabolic issues like fatty liver and diabetes, with no current cure.
- Researchers are testing tissue-specific gene therapy using adeno-associated virus (AAV) vectors in mice with a lipodystrophy model to see if they can effectively target fat or liver tissue.
- The study found that AAV vectors aimed at fat tissue helped restore fat development and improve metabolic health, while liver-targeted treatments had limited success, highlighting a promising therapeutic direction.
Case report: two novel PPARG pathogenic variants associated with type 3 familial partial lipodystrophy in Brazil.
Diabetol Metab Syndr
July 2024
Laboratório de Biologia Molecular e Genômica, Departamento de Biologia Celular e Genética, Centro de Biociências, Universidade Federal do Rio Grande do Norte - UFRN, Campus Universitário, Lagoa Nova, Natal, RN, 59072-970, Brazil.
Introduction And Aim: Type 3 Familial Partial Lipodystrophy (FPLD3) is a rare metabolic disease related to pathogenic PPARG gene variants. FPLD3 is characterized by a loss of fatty tissue in the upper and lower limbs, hips, and face. FPLD3 pathophysiology is usually associated with metabolic comorbidities such as type 2 diabetes, insulin resistance, hypertriglyceridemia, and liver dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!